Keyphrases
Clinical Outcomes
100%
Ulcerative Colitis
100%
Adalimumab
100%
Infliximab
100%
Single Center
100%
Previously Treated
100%
TNF Inhibitors
27%
Clinical Response
18%
Treatment Failure
18%
Clinical Remission
18%
Anti-TNF Agents
18%
Ulcerative Colitis Patient
18%
Clinical Practice
9%
Inflammatory Bowel Disease
9%
Clinical Setting
9%
Naïve Patients
9%
Registration Trial
9%
Fully Human
9%
Short-term Efficacy
9%
Infusion Reaction
9%
Anti-TNF Naive
9%
Colectomy Rate
9%
Second-line Agents
9%
Medicine and Dentistry
Patient with Ulcerative Colitis
100%
Cohort Analysis
100%
Adalimumab
100%
Infliximab
100%
TNF Inhibitor
45%
Ulcerative Colitis
27%
Tumor Necrosis Factor
9%
Side Effect
9%
Inflammatory Bowel Disease
9%
Infusion
9%
Population Research
9%
Colectomy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Ulcerative Colitis
100%
Infliximab
100%
Adalimumab
100%
Tumor Necrosis Factor Inhibitor
45%
Remission
18%
Population Study
9%
Side Effect
9%
Tumor Necrosis Factor
9%
Inflammatory Bowel Disease
9%
Immunology and Microbiology
Ulcerative Colitis
100%
Infliximab
100%
Adalimumab
100%
TNF Inhibitor
45%
Population Research
9%
Inflammatory Bowel Disease
9%
Tumor Necrosis Factor
9%